|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||19.80 - 20.63|
|52-week range||9.01 - 29.90|
|PE ratio (TTM)||N/A|
|Earnings date||8 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||33.50|
While small-cap stocks, such as Collegium Pharmaceutical Inc (NASDAQ:COLL) with its market cap of US$879.63m, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 57 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.
On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 54 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.
Collegium rocketed to a 22-month high Tuesday after striking a deal with Depomed to commercialize its painkiller Nucynta.
The FDA is working on ways to encourage the development of abuse-deterrent opioid pain relievers, and that's potentially bad news for this tiny biotech.